Carregant...
Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives
Proprotein convertase subtilisin/kexin type 9 (PCSK9), also known as neural apoptosis regulated convertase (NARC1), is a key modulator of cholesterol metabolism. PCSK9 increases the serum concentration of low-density lipoprotein cholesterol by escorting low-density lipoprotein receptors (LDLRs) from...
Guardat en:
| Publicat a: | Acta Pharmacol Sin |
|---|---|
| Autors principals: | , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Publishing Group
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5342665/ https://ncbi.nlm.nih.gov/pubmed/28112180 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/aps.2016.134 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|